1.82
-0.01 (-0.55%)
| Previous Close | 1.83 |
| Open | 1.89 |
| Volume | 4,541,616 |
| Avg. Volume (3M) | 3,278,522 |
| Market Cap | 116,688,208 |
| Price / Sales | 10.62 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2026 |
| Diluted EPS (TTM) | 4.09 |
| Current Ratio (MRQ) | 0.720 |
| Operating Cash Flow (TTM) | -64.05 M |
| Levered Free Cash Flow (TTM) | -35.91 M |
| Return on Assets (TTM) | -122.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Outlook Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -2.00 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 38.31% |
| % Held by Institutions | 16.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lvw Advisors, Llc | 30 Sep 2025 | 48,235 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Ascendiant Capital, 449.45%) | Buy |
| Median | 1.00 (-45.06%) | |
| Low | 0.500 (HC Wainwright & Co., -72.53%) | Hold |
| Average | 3.83 (110.44%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 1.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 05 Jan 2026 | 1.00 (-45.05%) | Hold | 0.543 |
| HC Wainwright & Co. | 02 Jan 2026 | 0.500 (-72.53%) | Hold | 0.660 |
| Ascendiant Capital | 22 Dec 2025 | 10.00 (449.45%) | Buy | 1.84 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development |
| 31 Dec 2025 | Announcement | Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD |
| 26 Dec 2025 | Announcement | Outlook Therapeutics Announces New Employment Inducement Grants |
| 19 Dec 2025 | Announcement | Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 |
| 24 Nov 2025 | Announcement | Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Announcement | Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |